Detail

Magnesium oxide

Description

Name: Magnesium oxide
Type: small molecule
Groups: approved
Indication: Magnesium hydroxide is used as a laxative to relieve occasional constipation (irregularity) and as an antacid to relieve indigestion, sour stomach, and heartburn.
Accession Number: DB01377 ( DB01377)
Description: Magnesium oxide is an inorganic compound that occurs in nature as the mineral periclase. In aqueous media combines quickly with water to form magnesium hydroxide. It is used as an antacid and mild laxative and has many nonmedicinal uses. [PubChem]
Structure:
Prescription Products:
NameDosageStrengthRouteMarketing StartMarketing EndCountry
B6 Plus TabtabletArrayoral31-12-197901-08-2002Canada
Calcium Magnesium TabtabletArrayoral31-12-197909-09-1996Canada
Citracleenpowder for solutionArrayoral01-01-1970Canada
Cyclo/magkitArrayArray09-03-2010US
Cyclo/mag 10mg/200mgkitArrayArray17-02-2010US
Kidmag Vitamins W Magnesium TabtabletArrayoral31-12-198902-10-1996Canada
Magnesium CapcapsuleArrayoral31-12-198312-06-2002Canada
Migralex Dr. Mauskoptablet, coatedArrayoral15-11-2009US
One To One Cal-mag Tab 500mgtabletArrayoral31-12-198517-09-1997Canada
Oral Purgativepowder for solutionArrayoral16-11-2011Canada
Pico-salaxpowder for solutionArrayoral25-11-2004Canada
Picodanpowder for solutionArrayoral17-10-200731-12-2012Canada
Picoflopowder for solutionArrayoral25-03-2011Canada
Prenate Startablet, coatedArrayoral05-06-2014US
Purg-odanpowder for solutionArrayoral16-02-2009Canada
Strovite One CapletstabletArrayoral04-05-2001US
Usana Active Calciumtablet, chewableArrayoral28-03-2012US
Virt-bal DHA PluskitArrayArray12-07-2012US
Virt-PNtablet, coatedArrayoral12-07-2012US
Virt-PN Pluscapsule, gelatin coatedArrayoral01-03-2013US

Generic Prescription Products: Not Available
Over the Counter Products:
NameDosageStrengthRouteMarketing StartMarketing EndCountry
Magnesium Citrate Oral Solutionliquid1.75 goral31-12-195111-07-2003Canada
Magnesium Oxidetablet400 mg/1oral08-09-2015US
Magnesium Oxidetablet400 mg/1oral15-07-2004US
Magnesium Oxidetablet400 mg/1oral01-01-2013US
Magnesium Oxidetablet400 mg/1oral09-04-2014US
Magnesium Oxidetablet400 mg/1oral30-09-2014US
Magnesium Oxidetablet400 mg/1oral03-12-2003US
Magnesium Oxidetablet253 mg/1oral06-10-2003US
Magnesium Oxide 420 - Caplettablet250 mgoral31-12-199518-07-2002Canada
Magnesium Oxide Tab 420mgtablet420 mgoral31-12-198817-07-2008Canada
Magnesium Tab 250mgtablet410 mgoral31-12-198705-07-2006Canada

International Brands
  • No Brands

Brand Names
  • No Brands

Brand Mixtures
Brand NameIngredients
Magnesium OxideMagnesium oxide
Magnesium OxideMagnesium oxide
Strovite One CapletsVitamin A + Pantothenic acid + Vitamin C + Cholecalciferol + Vitamin E + Thiamine + Riboflavin + Nicotinamide + Pyridoxine + Folic Acid + Biotin + Cyanocobalamin + Selenium + Magnesium oxide + Zinc oxide + Cupric sulfate + Manganese + Chromium + Lipoic Acid + Lutein
Magnesium OxideMagnesium oxide
Migralex Dr. MauskopAcetylsalicylic acid + Magnesium oxide
Usana Active CalciumCalcium carbonate + Magnesium oxide + Cholecalciferol + Calcium citrate + Magnesium citrate
Magnesium OxideMagnesium oxide
Magnesium OxideMagnesium oxide
Cyclo/magCyclobenzaprine + Magnesium oxide
Cyclo/mag 10mg/200mgCyclobenzaprine + Magnesium oxide
Magnesium OxideMagnesium oxide
Prenate StarBeta carotene + Vitamin C + Cholecalciferol + Thiamine + Riboflavin + Nicotinamide + Pyridoxine + Folic Acid + Cyanocobalamin + Biotin + Pantothenic acid + Formic Acid + Ferrous asparto glycinate + Potassium Iodide + Magnesium oxide + Zinc oxide + Cupric oxide
Magnesium OxideMagnesium oxide
Virt-bal DHA PlusFolic Acid + Pyridoxine + Calcium carbonate + Sodium ascorbate + Cholecalciferol + Acetic acid + Thiamine + Riboflavin + Nicotinamide + Cyanocobalamin + Ferrous bisglycinate + Iodine + Zinc oxide + Cupric oxide + Beta carotene + Magnesium oxide + Doconexent + Icosapent
Virt-PNLevomefolic acid + Pyridoxine + Beta carotene + Calcium carbonate + Vitamin C + Cholecalciferol + Vitamin E + Thiamine + Riboflavin + Nicotinamide + Cyanocobalamin + Iron + Potassium Iodide + Zinc oxide + Biotin + Pantothenic acid + Magnesium oxide + Cupric oxide
Virt-PN PlusFolic Acid + Vitamin C + Cholecalciferol + Vitamin E + Pyridoxine + Cyanocobalamin + Biotin + Calcium carbonate + Iron + Potassium Iodide + Magnesium oxide + Doconexent + Icosapent
Pico-salaxCitric Acid + Sodium picosulfate + Magnesium oxide
Purg-odanCitric Acid + Sodium picosulfate + Magnesium oxide
PicofloCitric Acid + Sodium picosulfate + Magnesium oxide
Oral PurgativeCitric Acid + Sodium picosulfate + Magnesium oxide
Magnesium Citrate Oral SolutionMagnesium oxide
Magnesium Oxide 420 - CapletMagnesium oxide
B6 Plus TabThiamine + Riboflavin + Pyridoxine + Niacin + Potassium Citrate + Magnesium oxide
Calcium Magnesium TabCalcium carbonate + Magnesium oxide
Magnesium CapMagnesium oxide + Magnesium Sulfate
One To One Cal-mag Tab 500mgCalcium + Magnesium oxide
PicodanCitric Acid + Sodium picosulfate + Magnesium oxide
Magnesium Tab 250mgMagnesium oxide
Magnesium Oxide Tab 420mgMagnesium oxide
Kidmag Vitamins W Magnesium TabPyridoxine + Vitamin C + Vitamin A + Magnesium oxide
CitracleenCitric Acid + Sodium picosulfate + Magnesium oxide

Categories
  • Antacids

Pharmacology

Indication: Magnesium hydroxide is used as a laxative to relieve occasional constipation (irregularity) and as an antacid to relieve indigestion, sour stomach, and heartburn.
Pharmacodynamics: Not Available
Mechanism of action: The term "Milk of Magnesia" was first used to describe a white aqueous, mildly alkaline suspension of magnesium hydroxide formulated at about 8%w/v. Milk of magnesia is primarily used to alleviate constipation, but can also be used to relieve indigestion and heartburn. When taken internally by mouth as a laxative, the osmotic force of the magnesia suspension acts to draw fluids from the body and to retain those already within the lumen of the intestine, serving to distend the bowel, thus stimulating nerves within the colon wall, inducing peristalsis and resulting in evacuation of colonic contents. Magnesium supplements have also been shown to reduce platelet aggregation by inhibiting in the influx of calcium, a crucial component of platelet aggregation.
Absorption: Not Available
Volume of distribution: Not Available
Protein binding: Not Available
Metabolism: Not Available
Route of elimination: Not Available
Half life: Not Available
Clearance: Not Available
Toxicity: Not Available
Affected organisms
  • Not Available

SNP Mediated Adverse Drug Reactions
  • Not Available

Pharmacoeconomics

Manufacturers:
  • Not Available

Packagers:
Dosage forms
FormRouteStrength
Kit
Capsuleoral
Liquidoral1.75 g
Tabletoral253 mg/1
Tabletoral400 mg/1
Tabletoral250 mg
Tabletoral420 mg
Tabletoral410 mg
Tablet, coatedoral
Powder for solutionoral
Tabletoral
Tablet, chewableoral
Capsule, gelatin coatedoral

Prices
Unit descriptionCostUnit
Magnesium oxide 250 mg tablet$0.03tablet
Magnesium oxide 500 mg tablet$0.04tablet
Maox 420 mg tablet$0.04tablet
Magnesium oxide powder heavy$0.05g
Mag-oxide 400 mg tablet$0.09tablet
Magnesium oxide 420 mg tablet$0.11tablet
Magox 400 tablet$0.11tablet
Magnesium oxide 400 mg tablet$0.13tablet
Phillips 500 mg caplet$0.18caplet

Patents
CountryPatent NumberApprovedExpires (estimated)

Interactions

Drug Interactions
DrugInteraction
AlendronateThe serum concentration of Alendronate can be decreased when it is combined with Magnesium oxide.
AlfacalcidolThe serum concentration of Magnesium oxide can be increased when it is combined with Alfacalcidol.
AllopurinolMagnesium oxide can cause a decrease in the absorption of Allopurinol resulting in a reduced serum concentration and potentially a decrease in efficacy.
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Magnesium oxide.
AmphetamineMagnesium oxide may decrease the excretion rate of Amphetamine which could result in a lower serum level and potentially a reduction in efficacy.
AmrinoneThe risk or severity of adverse effects can be increased when Amrinone is combined with Magnesium oxide.
AtazanavirMagnesium oxide can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.
AtorvastatinThe serum concentration of Atorvastatin can be decreased when it is combined with Magnesium oxide.
BenzphetamineMagnesium oxide may decrease the excretion rate of Benzphetamine which could result in a lower serum level and potentially a reduction in efficacy.
BepridilThe risk or severity of adverse effects can be increased when Bepridil is combined with Magnesium oxide.
BiotinMagnesium oxide can cause a decrease in the absorption of Biotin resulting in a reduced serum concentration and potentially a decrease in efficacy.
BisacodylThe therapeutic efficacy of Bisacodyl can be decreased when used in combination with Magnesium oxide.
BosutinibThe serum concentration of Bosutinib can be decreased when it is combined with Magnesium oxide.
BudesonideThe bioavailability of Budesonide can be decreased when combined with Magnesium oxide.
CalcitriolThe serum concentration of Magnesium oxide can be increased when it is combined with Calcitriol.
CaptoprilThe serum concentration of Captopril can be decreased when it is combined with Magnesium oxide.
CefditorenThe serum concentration of Cefditoren can be decreased when it is combined with Magnesium oxide.
CefpodoximeThe serum concentration of Cefpodoxime can be decreased when it is combined with Magnesium oxide.
CefuroximeThe serum concentration of Cefuroxime can be decreased when it is combined with Magnesium oxide.
ChloroquineThe serum concentration of Chloroquine can be decreased when it is combined with Magnesium oxide.
ChlorpromazineMagnesium oxide can cause a decrease in the absorption of Chlorpromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
CiprofloxacinMagnesium oxide can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
ClodronateThe serum concentration of Clodronate can be decreased when it is combined with Magnesium oxide.
Cortisone acetateThe bioavailability of Cortisone acetate can be decreased when combined with Magnesium oxide.
CysteamineThe therapeutic efficacy of Cysteamine can be decreased when used in combination with Magnesium oxide.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Magnesium oxide.
DabrafenibThe serum concentration of Dabrafenib can be decreased when it is combined with Magnesium oxide.
DasatinibMagnesium oxide can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
DeferiproneThe serum concentration of Deferiprone can be decreased when it is combined with Magnesium oxide.
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Magnesium oxide.
DemeclocyclineMagnesium oxide can cause a decrease in the absorption of Demeclocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
DexamethasoneThe bioavailability of Dexamethasone can be decreased when combined with Magnesium oxide.
DexmethylphenidateMagnesium oxide can cause an increase in the absorption of Dexmethylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
DextroamphetamineMagnesium oxide may decrease the excretion rate of Dextroamphetamine which could result in a lower serum level and potentially a reduction in efficacy.
DolutegravirThe serum concentration of Dolutegravir can be decreased when it is combined with Magnesium oxide.
DoxycyclineMagnesium oxide can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
EltrombopagThe serum concentration of Eltrombopag can be decreased when it is combined with Magnesium oxide.
ElvitegravirThe serum concentration of Elvitegravir can be decreased when it is combined with Magnesium oxide.
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Magnesium oxide.
FelodipineThe risk or severity of adverse effects can be increased when Felodipine is combined with Magnesium oxide.
FexofenadineThe serum concentration of Fexofenadine can be decreased when it is combined with Magnesium oxide.
FludrocortisoneThe bioavailability of Fludrocortisone can be decreased when combined with Magnesium oxide.
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Magnesium oxide.
FluphenazineMagnesium oxide can cause a decrease in the absorption of Fluphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
FluvastatinThe serum concentration of Fluvastatin can be decreased when it is combined with Magnesium oxide.
FosinoprilThe serum concentration of Fosinopril can be decreased when it is combined with Magnesium oxide.
GabapentinMagnesium oxide may increase the central nervous system depressant (CNS depressant) activities of Gabapentin.
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Magnesium oxide.
GemifloxacinMagnesium oxide can cause a decrease in the absorption of Gemifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
HexamethylenetetramineThe therapeutic efficacy of Hexamethylenetetramine can be decreased when used in combination with Magnesium oxide.
HydrocortisoneThe bioavailability of Hydrocortisone can be decreased when combined with Magnesium oxide.
HyoscyamineThe serum concentration of Hyoscyamine can be decreased when it is combined with Magnesium oxide.
IbandronateThe serum concentration of Ibandronate can be decreased when it is combined with Magnesium oxide.
IsoniazidMagnesium oxide can cause a decrease in the absorption of Isoniazid resulting in a reduced serum concentration and potentially a decrease in efficacy.
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Magnesium oxide.
ItraconazoleThe serum concentration of Itraconazole can be decreased when it is combined with Magnesium oxide.
KetoconazoleThe serum concentration of Ketoconazole can be decreased when it is combined with Magnesium oxide.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Magnesium oxide.
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Magnesium oxide.
LercanidipineThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Magnesium oxide.
LevofloxacinMagnesium oxide can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
LevothyroxineThe serum concentration of Levothyroxine can be decreased when it is combined with Magnesium oxide.
Lipoic AcidMagnesium oxide can cause a decrease in the absorption of Lipoic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
LisdexamfetamineMagnesium oxide may decrease the excretion rate of Lisdexamfetamine which could result in a lower serum level and potentially a reduction in efficacy.
LovastatinThe serum concentration of Lovastatin can be decreased when it is combined with Magnesium oxide.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Magnesium oxide.
MesalazineThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Magnesium oxide.
MethamphetamineMagnesium oxide may decrease the excretion rate of Methamphetamine which could result in a lower serum level and potentially a reduction in efficacy.
MethotrimeprazineMagnesium oxide can cause a decrease in the absorption of Methotrimeprazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
MethylphenidateMagnesium oxide can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
MethylprednisoloneThe bioavailability of Methylprednisolone can be decreased when combined with Magnesium oxide.
MinocyclineMagnesium oxide can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
MisoprostolThe risk or severity of adverse effects can be increased when Magnesium oxide is combined with Misoprostol.
MoxifloxacinMagnesium oxide can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Mycophenolate mofetilMagnesium oxide can cause a decrease in the absorption of Mycophenolate mofetil resulting in a reduced serum concentration and potentially a decrease in efficacy.
Mycophenolic acidThe serum concentration of Mycophenolic acid can be decreased when it is combined with Magnesium oxide.
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Magnesium oxide.
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Magnesium oxide.
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Magnesium oxide.
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Magnesium oxide.
NitrendipineThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Magnesium oxide.
NorfloxacinMagnesium oxide can cause a decrease in the absorption of Norfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
OfloxacinMagnesium oxide can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
OxytetracyclineMagnesium oxide can cause a decrease in the absorption of Oxytetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
PazopanibThe serum concentration of Pazopanib can be decreased when it is combined with Magnesium oxide.
PenicillamineThe serum concentration of Penicillamine can be decreased when it is combined with Magnesium oxide.
PerhexilineThe risk or severity of adverse effects can be increased when Perhexiline is combined with Magnesium oxide.
PerphenazineMagnesium oxide can cause a decrease in the absorption of Perphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
PhendimetrazineMagnesium oxide may decrease the excretion rate of Phendimetrazine which could result in a lower serum level and potentially a reduction in efficacy.
PhentermineMagnesium oxide may decrease the excretion rate of Phentermine which could result in a lower serum level and potentially a reduction in efficacy.
PipotiazineMagnesium oxide can cause a decrease in the absorption of Pipotiazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
PitavastatinThe serum concentration of Pitavastatin can be decreased when it is combined with Magnesium oxide.
Polystyrene sulfonateThe risk or severity of adverse effects can be increased when Magnesium oxide is combined with Polystyrene sulfonate.
PravastatinThe serum concentration of Pravastatin can be decreased when it is combined with Magnesium oxide.
PrednisoloneThe bioavailability of Prednisolone can be decreased when combined with Magnesium oxide.
PrednisoneThe bioavailability of Prednisone can be decreased when combined with Magnesium oxide.
PrenylamineThe risk or severity of adverse effects can be increased when Prenylamine is combined with Magnesium oxide.
ProchlorperazineMagnesium oxide can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
PromazineMagnesium oxide can cause a decrease in the absorption of Promazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
QuinidineMagnesium oxide may decrease the excretion rate of Quinidine which could result in a lower serum level and potentially a reduction in efficacy.
QuinineThe serum concentration of Quinine can be decreased when it is combined with Magnesium oxide.
RaltegravirThe serum concentration of Raltegravir can be decreased when it is combined with Magnesium oxide.
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Magnesium oxide.
RiociguatThe serum concentration of Riociguat can be decreased when it is combined with Magnesium oxide.
RisedronateThe serum concentration of Risedronate can be decreased when it is combined with Magnesium oxide.
RosuvastatinThe serum concentration of Rosuvastatin can be decreased when it is combined with Magnesium oxide.
SimvastatinThe serum concentration of Simvastatin can be decreased when it is combined with Magnesium oxide.
SofosbuvirThe serum concentration of Sofosbuvir can be decreased when it is combined with Magnesium oxide.
SotalolThe serum concentration of Sotalol can be decreased when it is combined with Magnesium oxide.
SparfloxacinThe serum concentration of Sparfloxacin can be decreased when it is combined with Magnesium oxide.
TetracyclineMagnesium oxide can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
ThioridazineMagnesium oxide can cause a decrease in the absorption of Thioridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
TiludronateThe serum concentration of Tiludronate can be decreased when it is combined with Magnesium oxide.
TriethylenetetramineThe serum concentration of Magnesium oxide can be decreased when it is combined with Triethylenetetramine.
TrifluoperazineMagnesium oxide can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Magnesium oxide.

Food Interactions:
  • Not Available

Taxonomy

Kingdom: Inorganic compounds
Super Class: Not Available
Class: Not Available
Sub Class: Not Available
Direct Parent: Not Available
Alternative Parents:

    substituent:
    • Acyclic compound
    • Inorganic oxide
    • Miscellaneous mixed metal/non-metal

    References

    Synthesis Reference: Jajnya D. Panda, Santosh K. Mahapatra, "Process for the production of magnesium oxide from brine or bittern." U.S. Patent US4370422, issued June, 1921.
    General Reference: # Kh R, Khullar M, Kashyap M, Pandhi P, Uppal R: Effect of oral magnesium supplementation on blood pressure, platelet aggregation and calcium handling in deoxycorticosterone acetate induced hypertension in rats. J Hypertens. 2000 Jul;18(7):919-26. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10930190 # Shechter M, Merz CN, Paul-Labrador M, Meisel SR, Rude RK, Molloy MD, Dwyer JH, Shah PK, Kaul S: Oral magnesium supplementation inhibits platelet-dependent thrombosis in patients with coronary artery disease. Am J Cardiol. 1999 Jul 15;84(2):152-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10426331
    External Links:
    ResourceLink
    Drugs.comhttp://www.drugs.com/cdi/magnesium-oxide.html

    ATC Codes:
    • Array
    • Array
    • Array

    AHFS Codes:
    • 88:29.00*
    • 92:02.00*

    MSDS: Download
    SiteLock

    © Copyright 2022 The Purple Society, Purple Gladiator, Trialsmap, The Purple Drug Guide, and One Person CAN Make A Difference! are all registered trademarks of The Purple Society. The Purple Society, a not-for-profit, section 501(c)(3) #273785281.

    The Purple Society website is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through this site should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, you should consult your health care provider.

    CONTACT US

    The Purple Society team is here for you 24 hours a day, 7 days a week. Send us an email and we'll get right back to you.

    Sending
    or

    Log in with your credentials

    Forgot your details?